BioFocus DPI will use the high purity, clinical grade human motor neurons to perform assay development and screening for amyotrophic lateral sclerosis (ALS or ‘Lou Gehrig’s disease’) drug discovery on behalf of The ALS Association’s Treat ALS drug discovery and clinical trials program.
The ALS Association’s Treat ALS (Translational Research Advancing Therapy for ALS) program is funding this collaborative research project as part of its global initiative to speed the discovery of new drugs and therapies for ALS.
Katherine Hilyard, vice president of biological sciences, BioFocus DPI, said: “BioFocus DPI chose to source human motor neurons from CSC because its multi-well plate format enables us to develop specialized high-throughput assays not previously possible. This is the first source of high purity human motor neurons available for use in high-content screening assays. This significant advancement allows us to develop innovative human cell-based assays for the discovery of drugs for ALS and other neurological disorders.”